paliperidone-palmitate has been researched along with Movement-Disorders* in 5 studies
1 trial(s) available for paliperidone-palmitate and Movement-Disorders
Article | Year |
---|---|
Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
This study aims to determine the effectiveness of paliperidone extended release (ER) on cognitive function in patients with schizophrenia in comparison with risperidone. This was a 12-week, randomized, open-label study on schizophrenia patients who were receiving risperidone. The patients were randomized to a risperidone-continuation group or a paliperidone-switch group. The primary outcome measure was neurocognitive function, which was measured using a computerized battery. Secondary efficacy measures included the Positive and Negative Syndrome Scale, Social and Occupational Functioning Scale, and Calgary Depression Scale for Schizophrenia. In total, 58 patients participated in this trial. Improvements in recall after an interference phase in the verbal learning test were significantly greater in the paliperidone-switch than in the risperidone-continuation group. No significant differences in changes were observed in the other six neurocognitive domains measured. Improvements in the Social and Occupational Functioning Scale were significantly greater in the paliperidone ER-switch group than in the risperidone-continuation group. In other efficacy outcome measures, no significant differences were observed between the two drugs. Paliperidone ER had a side-effect profile similar to that of risperidone, including metabolic problems and prolactin-related adverse events. In conclusion, switching from risperidone to paliperidone ER may lead to additional cognitive and social functional improvements. Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Delayed-Action Preparations; Depression; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Monitoring; Female; Humans; Isoxazoles; Male; Middle Aged; Movement Disorders; Paliperidone Palmitate; Prevalence; Psychiatric Status Rating Scales; Pyrimidines; Republic of Korea; Risperidone; Schizophrenia; Young Adult | 2012 |
4 other study(ies) available for paliperidone-palmitate and Movement-Disorders
Article | Year |
---|---|
Improvement of mitochondrial function by paliperidone attenuates quinolinic acid-induced behavioural and neurochemical alterations in rats: implications in Huntington's disease.
Quinolinic acid (QA)-induced neurotoxicity involves a cascade of events such as increased calcium concentration in cytoplasm, exhaustive ATP depletion, oxidative stress, as well as selective GABAergic, dopaminergic, and cholinergic neuronal death. Clinical data hint towards the connection between signalling of dopaminergic system and efficient amelioration of chorea following a tetrabenazine administration in Huntington's disease patients. Therefore, the present study has been designed to explore the neuroprotective potential of paliperidone, an active metabolite of risperidone (a dopaminergic antagonist) against QA-induced neurotoxicity and related complications in rats. QA (200 nmol) was administered bilaterally to the striatum over a period of 2 min by means of a 28-gauge stainless steel needle attached to a Hamilton syringe. The study protocol involves seven treatment groups (n = 12): naïve, sham, control (QA), paliperidone (0.5, 1 and 2 mg/kg) and paliperidone (2) per se. Single bilateral intrastriatal injection of QA (200 nmol/2 μl saline) significantly caused motor incordination, memory impairment, oxidative damage, decrease in biogenic amines levels, cellular alterations (TNF-α, IL-6, PGE2, PGF2α, caspase-3, BDNF, mitochondrial function) and damage of striatal neurons compared to the sham treatment. Treatment with paliperidone (0.5, 1 and 2 mg/kg) for 21 days significantly attenuated the QA-induced behavioural (motor and memory function), neurochemical (antioxidant enzymes and biogenic amines) and cellular alterations, as well as striatal neurodegeneration. The study indicated that modulation of dopaminergic pathway by paliperidone treatment could be a useful approach in the management of motor and memory abnormality in HD patients. Topics: Acetylcholinesterase; Animals; Biogenic Amines; Body Weight; Corpus Striatum; Huntington Disease; Isoxazoles; Male; Maze Learning; Memory Disorders; Mitochondria; Movement Disorders; Neurons; Neuroprotective Agents; Oxidative Stress; Oxygen; Paliperidone Palmitate; Pyrimidines; Quinolinic Acid; Rats, Wistar | 2014 |
Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases.
To assess the tardive dyskinesia (TD) rate in studies of once-monthly long-acting injectable (LAI) paliperidone palmitate (PP) and once-daily oral paliperidone extended release (Pali ER).. Completed schizophrenia and bipolar studies for PP and Pali ER (≥ 6 month duration with retrievable patient-level data) were included in this post hoc analysis. Schooler-Kane research criteria were applied using Abnormal Involuntary Movement Scale (AIMS) scores to categorise probable (qualifying AIMS scores persisting for ≥ 3 months) and persistent TD (score persisting ≥ 6 months). Spontaneously reported TD adverse events (AEs) were also summarised. Impact of exposure duration on dyskinesia (defined as AIMS total score ≥ 3) was assessed by summarising the monthly dyskinesia rate.. In the schizophrenia studies, TD rates for PP (four studies, N = 1689) vs. Pali ER (five studies, N = 2054), were: spontaneously reported AE, 0.18% (PP) vs. 0.10% (Pali ER); probable TD, 0.12% (PP) vs. 0.19% (Pali ER) and persistent TD, 0.12% (PP) vs. 0.05% (Pali ER). In the only bipolar study identified [Pali ER (N = 614)], TD rate was zero (spontaneously reported AE reporting, probable and persistent TD assessments). Dyskinesia rate was higher within the first month of treatment with both PP (13.1%) and Pali ER (11.7%) and steadily decreased over time (months 6-7: PP: 5.4%; Pali ER: 6.4%). Mean exposure: PP, 279.6 days; Pali ER, 187.2 days.. Risk of TD with paliperidone was low (< 0.2%), regardless of the formulation (oral or LAI), in this clinical trial dataset. Longer cumulative exposure does not appear to increase the risk of dyskinesias. Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Movement Disorders; Paliperidone Palmitate; Recurrence; Risperidone; Schizophrenia; Treatment Outcome | 2014 |
Paliperidone-induced tardive dystonia: a case report.
Topics: Adult; Antipsychotic Agents; Female; Humans; Isoxazoles; Movement Disorders; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2013 |
Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Isoxazoles; Movement Disorders; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia | 2011 |